Alofisel Launching

project
project
project
project
project
project
project
project
project
project

Challenge​

Among the many complications from Crohn's disease, one especially is perianal fistulas. As a response to this problem, the first allogeneic cell therapy, indicated for the treatment of complex perianal fistulas, has been developed and manufactured entirely in Spain.

Our mission was to create staging for the launching to rise the occasion.

Solution​​

To give the event a context, we created a strategic concept that would convey the key aspects of therapy innovatively and elegantly.
Thus arose Biomimetical, forms full of life. An idea based on the imitation of nature as a source of inspiration for solutions linking the bionic architecture with the drug indication.

The environment in which the meeting would take place played a fundamental role therefore the venue was specially selected based on its characteristics per the concept. Using the decoration, we established similar relationships between the shapes of the building and different natural elements (a cave, a gorge, the elephant skin)

We turned the stage into a representation of the operation of the product by assembling a structure formed by methacrylate tubes were filled with different audiovisual forms, customized according to the theme of each presentation

We have the presence of top-level speakers, such as Fernando de la Portilla, Julián Panés, and Damián García-Olmo, the researchers involved in the development of the drug; the president of the SEFH, Olga Delgado; the Spanish architect Javier Pioz, a pioneer in Bionic Architecture; and an exceptional moderator, David Cantero.

Results​

The meeting was attended by more than 100 healthcare professionals from different specialties (coloproctologist surgeons, gastroenterologists, pharmacists, etc), who shown great satisfaction for several aspects of the event, such as the creation of spectacular space with great decoration, a surprising performance, and an illustrative content with maximum interest.